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Abstract: Selective inhibition of tumor-associated carbonic anhydrase (CA; EC 4.2.1.1) isoforms IX
and XII is a crucial prerequisite to develop successful anticancer therapeutics. Herein, we confirmed
the efficacy of the 3-nitrobenzoic acid substructure in the design of potent and selective carboxylic
acid derivatives as CAs inhibitors. Compound 10 emerged as the most potent inhibitor of the
tumor-associated hCA IX and XII (Ki = 16 and 82.1 nM, respectively) with a significant selectivity
with respect to the wide spread hCA II. Other 3-nitrobenzoic acid derivatives showed a peculiar CA
inhibition profile with a notable potency towards hCA IX.
Keywords: carbonic anhydrase inhibitors (CAIs); carboxylic acid; tumor-associated isoforms; isoform
selectivity; molecular modeling
1. Introduction
Carbonic Anhydrases (CAs; EC 4.2.1.1) are ubiquitous Zn-dependent metalloenzymes that
catalyze the interconversion of carbon dioxide (CO2) to bicarbonate ion (HCO3−). To date, 16 isoforms
have been characterized in humans and are involved in many physiological and physio-pathological
processes, like the regulation of pH and acid–base homeostasis, CO2 elimination, bone resorption,
electrolyte secretion, gluconeogenesis, ureagenesis, and tumorigenesis [1,2].
Nowadays, there are at least 25 CA inhibitors (CAIs) used in the clinical practice or in clinical
development for the treatment of glaucoma [3], epilepsy [4], ulcers [5], infectious diseases [6–8],
osteoporosis [9], obesity [10], Alzheimer’s disease [6], and cancer [11], which highlight CAs as
profitable drug targets for pharmacological intervention. Targeting specific CA isoforms has
been indeed exploited in the therapy of different diseases. Human CA II (hCA II), hCA IV,
and hCA XII are usually referred as anti-glaucoma drug targets [3,12–14], hCA IX and hCA XII
are well-known tumor-associated isoforms [15–18], hCA VA is a promising drug target for the
treatment of obesity [19–21], while hCA VII is a drug target for the treatment of neuropathic pain and
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epilepsy [1,22–24]. Coupled with ubiquitous expression and with their critical role in cell homeostasis,
indiscriminate inhibition of many hCA isoforms at the same time may lead to detrimental side
effects. Although the design of CAIs is a consolidated strategy in drug discovery, the development of
isoform-selective CAIs still represents one of the major challenges for CA-related medicinal chemistry
and drug development [25].
Recently, we have established an in silico target fishing approach to recycle a false-positive hit
(namely GV2-20, Figure 1A) highlighted in a 14-3-3 cell-based screening [26–29]. Particularly, GV2-20
bears a carboxylic acid group and showed potent inhibition of hCAs with remarkable selectivity for
hCA II, hCA VII, hCA IX, and hCA XII. Interestingly, among CAIs with carboxylic acid group, GV2-20
possessed a new scaffold, thus becoming a privileged molecule for further development with potential
use as diagnostic and therapeutic tool.
Among established Zn-binding groups such as hydroxamic acid, thiol, phenols, and sulfonamide,
carboxylic acid is widely used in substrates and inhibitors of different classes of metalloproteins
such as CAs [30,31], matrix metalloproteinases (MMPs) [32–35], angiotensin converting enzyme
(ACE) [36], Zmp1 from Mycobacterium tuberculosis [37], COP9 signalosome subunit 5 (CSN5) [38],
and tyrosinase [39] for its ability to coordinate the metal center. Different from well-known chemotypes
of CAIs such as for instance sulfamides, sulfonamides, and their derivatives whose interaction with
CAs has been extensively characterized by X-ray crystallography [25,40], structural features of potent
and selective CAIs based on carboxylic acid is poorly elucidated yet. X-ray crystallography studies
performed on hCA II have highlighted two binding sites for carboxylic acid CAIs, located within
the catalytic cavity [41], or in a pocket that is commonly referred as “out of the binding site” [42].
Notably, a number of low molecular weight (MW) benzoic acids proved to bind simultaneously to
both these sites [43]. Among the catalytic site binders, we can include carboxylic acid derivatives
that bind directly the catalytic Zn(II) ion in a tetrahedral geometry, as well as those anchored to the
Zn(II)-coordinated water molecule [44–46]. An additional class of carboxylic acid precursors that
showed inhibition of hCAs are coumarin and thiocumarin derivatives, which are hydrolyzed by the
esterase CAs activity, thus partially occluding the entrance of the catalytic cavity, as highlighted by
structural studies [47,48].
However, despite their potentiality as CAIs, currently available structural data are not sufficient
to clarify the requirements of carboxylic acid CAIs for binding to hCAs, which also contributed to
explain the lower efforts dedicated to this class compared to widely explored sulfonamides and
sulfamides [30].
To further explore the molecular determinants responsible for potent and selective inhibition of
hCAs by carboxylic acids, here we used the tail approach to design a number of derivatives of the
previous CAI hit GV2-20. Indeed, this is a versatile tool to design and optimize hit and lead CAIs
possibly improving potency and selectivity [49,50]. Our previous results showed that the symmetric
3,5-dinitrobenzoic acid moiety of GV2-20 binds preferentially the catalytic site, thus becoming the
head of the molecular scaffold; accordingly, the tail moiety is expected to bind the external and highly
variable region of hCAs [51] and enhance selectivity inhibition. Following this strategy, 17 compounds
(namely, compounds 1–17, Figure 2) bearing the common 3-nitrobenzoic acid substructure (Figure 1B)
and having a significant chemical diversity each other were retrieved by filtration of a commercial
database. In addition, two compounds bearing modifications to the head portion of GV2-20 were
selected (namely, compounds 18 and 19, Figure 2) to substantiate the pharmacophoric relevance of
the selected 3-nitrobenzoic acid head. Inhibitory properties of 1–19 were profiled against a panel of
recombinant hCAs. The possible binding mode of the most interesting CAIs in terms of potency and
selectivity was investigated by molecular modeling against tumor-associated hCA IX and hCA XII.
Results of this multidisciplinary effort provide additional insights to the possible binding of CAIs
bearing carboxylic acid moiety and set the bases for further investigations.
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Figure 1. (A) GV2-20 chemical structure; (B) GV2-20 substructure used to filter MolPort database 
represented as 2D structure (top) and SMART description (bottom). 
 
Figure 2. Chemical structure of selected GV2-20 derivatives. Head portions are colored red, tails are 
colored blue. 
2. Results and Discussion 
2.1. Substructure Search and Ligands Selection 
To pursue the tail approach on the previously identified hit GV2-20, we selected the 3-
nitrobenzoic acid substructure as head (Figure 1B, top). Indeed, carboxylic acid is a well-known 
pharmacophore that has been widely exploited in the design of small molecule inhibitors of 
metalloproteins [52,53]. 
A fast and efficient way to extract molecules with a specific substructure from chemical libraries 
is to use SMART- or fingerprint-based filtration. Here we used the SMART string described in Figure 
1B (bottom panel) that corresponds to the 3-nireobenzoic acid to extract 1111 commercially available 
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Figure 2. Chemical structure of selected GV2-20 derivatives. Head portions are colored red, tails are
colored blue.
2. Results and Discussion
2.1. Substructure Search and Ligands Selection
To pursue the tail approach on the previously identified hit GV2-20, we selected the 3-nitrobenzoic
acid substructure as head (Figure 1B, top). Indeed, carboxylic acid is a well-known pharmacophore
that has been widely exploited in the design of small molecule inhibitors of metalloproteins [52,53].
A fast and efficient way to extract molecules with a specific substructure from chemical libraries is
to use SMART- or fingerprint-based filtration. Here we used the SMART string described in Figure 1B
(bottom panel) that corresponds to the 3-nireobenzoic acid to extract 1111 commercially available
molecules bearing the selected substructure from the MolPort database (consisting of more than
6 million entries at the time of our experiments, April 2016).
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Chemical diversity of filtered compounds was then evaluated, and a subset of nineteen
compounds (1–19, Figure 2) endowed with tails that differ in chemical, shape, and electronic properties
from each other was selected for CAs inhibition assays. Tail groups of 1–19 include amide, sulfone,
sugar, aromatic, aliphatic, heteroaromatic, and heterocyclic moieties. MW of 1–19 ranges from 231 to
480. This subset is expected to enhance selectivity and potency of the reference inhibitor GV2-20.
Besides 3-nitrobenzoic acid derivatives and with the aim to evaluate the relevance of the head
group in CA inhibition, we also included in our selection compound 18, which lacks the nitro group in
the head, and 19, where the carboxylic acid group is replaced by a nitrile group.
2.2. Carbonic Anhydrase Inhibition
Compounds 1–19 were tested for their inhibitory activity against pharmacologically relevant
hCA isoforms by means of the stopped-flow CO2 hydrase assay [54], using as reference compound
acetazolamide (AAZ). hCAs inhibition data are reported in Table 1, together with the values measured
previously for GV2-20 [26], which are included in Table 1 to facilitate comparison.
Overall, it is clear from Table 1 that, compared to GV2-20, all tested compounds showed
a decreased efficacy against hCA I, hCA II, hCA IV, and hCA VII, and notably improved their potency
of inhibition against hCA IX, which contributed to the increased selectivity observed towards this
latter isoform.
Further analysis of Table 1 led to draw the following structure–activity relationships (SAR):
(i) All tested compound are poorly active against cytosolic hCA I and hCA II, as Ki values were
significantly higher with respect to the reference compounds AAZ and GV2-20. The drop of
inhibitory potency compared to GV2-20 is particularly marked against hCA II, where the most
potent inhibitor of the series, namely compound 1, has a Ki around 54-fold higher than that of AAZ
and around 10-fold higher than that of GV2-20. Sub-micromolar inhibition of hCA I was observed
only for compounds 1 and 8, bearing respectively a 1,3,4-oxadiazole and a 1,3,4-thiadiazole
moiety in the tail, while 1 was the only hCA I inhibitor with sub-micromolar Ki. Modifications to
the heterocycle such as the tetrazole in 17 proved ineffective for hCA II inhibition. Other tested
compounds showed Ki in the micromolar range, or proved inactive at all against these cytosolic
hCA isoforms.
(ii) Similar to the reference inhibitor GV2-20 but different from AAZ, tested compounds proved
generally inactive also against hCA IV.
(iii) Compared to GV2-20, most of tested compounds showed a significant improvement of hCA
VA inhibition. Notably, the most potent hCA VA inhibitor of the series was 19, in which the
carboxylic acid is replaced by the nitrile function thus opening new venues for the design of
hCA VA-specific inhibitors. Other compounds with a low Ki against this isoform are 10, 12, 13,
15, and 16 that also show a certain degree of specificity for hCA VA particularly compared to
cytosolic hCA I and hCA II, hCA IV, and hCA VII.
(iv) Most of tested compound were poorly active against hCA VII that, in contrast, was efficiently
inhibited by GV2-20 and AAZ. As already observed for hCA I and hCA II, compound 1 was
the most potent inhibitor of hCA VII, even though the chemically-related compound 8 proved
inactive. Compared to GV2-20, compound 1 showed around 37-fold drop of inhibitory potency
against hCA VII. Moreover, 5, 13, and 19 that are structurally-related to GV2-20 proved inactive.
This suggests that subtle modifications to GV2-20 scaffold have a dramatic impact on hCA VII
inhibition, and that the 3,5-dinitrobenzoic acid is required to target this hCA isoform.
(v) Tumor-associated isoforms hCA IX and hCA XII were potently inhibited by most of tested
compounds. It is worth noting that some compounds showed stronger or at least similar inhibition
of hCA IX compared to the reference compounds AAZ and GV2-20, see for example 6–8, 10,
14–17, whereas none of them was able to overtake AAZ or GV2-20 against hCA XII. The most
potent inhibitor of hCA IX was 10, which also inhibited hCA XII in the low nanomolar range.
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Unique among other is the behavior of compounds 6 and 7, which are low nanomolar inhibitors
of CA IX with potency comparable to AAZ, although they are not active against hCA XII. Of
note, 7 is the lowest MW compound of the test-set, thus becoming the selective hCA IX inhibitor
endowed with the highest ligand efficiency identified in this work [55]. Therefore, its structure
could be easily expanded by rational design with the aim to optimize physicochemical and
pharmacological properties up to the level of confirmed lead or preclinical candidate. Finally,
since hCA II is the most physiologically abundant hCA isoform, and is generally referred as
the major causes of CAIs side-effects [1], the hCA II/hCA IX and hCA II/hCA XII selectivity
indexes are showed in Table 1. Notably, the most potent inhibitors of tumor-associated hCA
IX and hCA XII isoforms are also significantly selective with respect to the cytosolic hCA II.
While all compounds showed a greater selectivity than the reference inhibitors GV2-20 and AAZ,
compound 1 showed the weakest specificity for tumor-associated hCAs, whereas 10 emerged as
the most selective one.
(vi) The GV2-20 derivative 18 that is deprived of the nitro group in the head portion is poorly
active in most hCA isoforms, with the only exception of hCA IX, for which it showed a Ki of
72.8 nM. Based on the comparison with the hCAs inhibition profile of GV2-20, we may speculate
that at least one nitro group in the head portion is essential for the efficient inhibition of most
hCAs. Compound 19 that bears a nitrile instead of carboxylic acid group, shares a similar hCAs
inhibition profile as 18 with the exception of a stronger inhibition of hCA VA (Ki = 92.5 nM).
In summary, SAR analysis highlighted compound 1 as an interesting pan-hCAs inhibitor with
a moderate selectivity for tumor-associated hCA IX and hCA XII with respect to cytosolic hCA II and
hCA VA, while 10 proved to be an attractive low MW anticancer lead candidate endowed with potent
and selective inhibition of hCA IX and hCA XII. The highest efficiency ligand 7 emerged as selective
inhibitor of hCA IX, particularly with respect to hCA XII, which paves the way to the design of tool
compounds for isoform-specific modulation of hCA IX. The 3-nitrobenzoic acid substructure was
confirmed as privileged head for the design of potent and selective carboxylic acid CAIs.
Table 1. Inhibition data of hCA I, hCA II, hCA IV, hCA VA, hCA VII, hCA IX, hCA XII with
compounds 1–19, GV2-20, and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped
flow CO2 hydrase assay.
Cmpd Ki (nM) a Selectivity Index b
hCA I hCA II hCA IV hCA VA hCA VII hCA IX hCA XII hCA II/hCA IX hCA II/hCA XII
1 700 655 5090 826 325 55.1 27.3 11.88 23.99
2 5645 7240 >50,000 1352 >50,000 106 >50,000 68.3 -
3 >50,000 7300 >50,000 1314 840 209 >50,000 34.9 -
4 6020 2630 >50,000 >50,000 >50,000 172 >50,000 15.3 -
5 8150 >50,000 >50,000 1163 >50,000 153 863 >326.8 >57.9
6 8210 8050 >50,000 >50,000 >50,000 30.6 >50,000 263.1 -
7 >50,000 7310 >50,000 1456 >50,000 27.6 >50,000 264.9 -
8 6450 801 8800 >50,000 >50,000 26.3 912 30.4 0.9
9 >50,000 8500 8270 >50,000 762 165 753 51.5 11.3
10 6650 >50,000 >50,000 142 665 16.0 82.1 >3125 >609.01
11 >50,000 >50,000 >50,000 356 >50,000 58.3 778 >857.6 >64.3
12 >50,000 >50,000 >50,000 144 >50,000 82.0 91.9 >609.0 >544.1
13 >50,000 >50,000 >50,000 117 >50,000 106 633 >471.7 >79.0
14 >50,000 >50,000 >50,000 449 >50,000 23.0 482 >2174.0 >103.7
15 >50,000 >50,000 9200 110 >50,000 24.7 724 >2024.3 >69.1
16 >50,000 >50,000 6030 154 1733 30.1 352 >1661.1 >142.0
17 >50,000 >50,000 3560 739 >50,000 23.4 441 >2136.8 >113.4
18 2730 7630 >50,000 262 >50,000 72.8 629 104.8 12.1
19 >50,000 >50,000 >50,000 92.5 >50,000 79.1 648 >632.1 77.2
GV2-20 352 67.3 7660 895 8.7 42.3 9.6 1.59 7.01
AAZ 250 12.1 74.3 63.5 2.6 25.0 5.7 0.48 2.12
a Errors in the range of ± 5–10% of the reported values, from 3 different assays (data not shown); b Selectivity index
was not calculated for compounds showing Ki > 50,000 nM for inhibition of hCA XII.
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2.3. Molecular Modeling Study
Since the binding mode of carboxylic acid CAIs is highly variable [47], and our crystallization
trials were unsuccessful, we performed a molecular modeling study to provide structural support
(where possible) to SAR and selectivity profiles of the most interesting hCAIs identified in this work.
Based on Table 1, and considering that the parent compound GV2-20 showed antiproliferative effects
on chronic myeloid leukemia cells [26], tumor-associated hCA IX and hCA XII isoforms were selected
for this task. Compounds 1, 7, 10, 15, and 19 were docked against the crystallographic structure of hCA
IX, while 1, 7, and 10 were docked towards hCA XII. Indeed, 1 was an interesting pan-CAs inhibitor
with a moderate specificity for hCA IX and hCA XII; 7 was the lowest MW compound showing very
potent inhibition of hCA IX with no effects on hCA XII; 10 was the most potent inhibitor of hCA IX
showing a good inhibition of hCA XII and the highest selectivity with respect to the cytosolic and
widely expressed hCA II; 15 and 19 showed a remarkable potency and selectivity against hCA IX and
hCA XII, and were notably active against hCA VA for which no crystal structures are available to date.
For the sake of clarity, in our study we addressed three different binding modes hypothesis:
(i) direct binding of the carboxylic acid group to the catalytic Zn(II) ion; (ii) binding of carboxylic acid
group to the Zn(II)-coordinated water molecule; and (iii) binding “out of the binding site”. Results
discussed thereafter refer to the most reliable binding poses that were generated according to binding
mode hypothesis (ii), namely carboxylic acid CAIs that bind the catalytic Zn(II) ion through a bridging
water molecule. Docking poses were then refined by energy minimization in explicit water solvent.
The binding modes toward hCA IX are showed in Figure 3. The carboxylic acid group of 1, 7,
10, and 15 binds the Zn(II)-coordinated water molecule while compound 19, in which the carboxylic
acid is replaced by a nitrile group, does not, which may account for lower inhibition potency of this
compound against hCA IX. Besides anchoring the Zn(II)-coordinated water molecule, the carboxylic
acid group of compounds 1, 7, and 15 performs additional H-bonds with the side chain of Thr-199
and Thr-200 (Figure 3A,B,D). The nitro group of all compounds is H-bonded to the side chain of
Gln-67 with the exception of compound 10 and 15 in which it is H-bonded to Asn-62 (Figure 3C,D).
The tail groups of compounds 1, 7 and 10 are H-bonded to Gln-92, while compound 15 establishes
an H-bond with the side chain of Trp-5. Moreover, the aromatic ring in the tail of 1, 10, and 19 and
the methyl group of 8 are docked within a hydrophobic cleft of hCA IX residues formed by Leu-89,
Val-119, Val-128, and Leu-197.
Predicted binding modes towards hCA XII are showed in Figure 4. The carboxylic acid group of
compounds 1 and 10 is able to bind the catalytic Zn(II) ion by means of a bridging water molecule
(Figure 4A,C). In addition, it is found to bind Gln-92 side chain in the case of 1 and Thr-199 and Thr-200
in the case of 10. The nitro group of compound 1 is H-bonded with Asn-62 and Thr-200, while the same
group of compound 10 binds the side-chain of Lys-67. Moreover, the tail of compound 10 performed
an additional H-bond with Gln-92, as already observed in hCA IX (Figure 4C).
Of particular interest is the analysis of the binding-mode of compound 7 because docking
simulations were unable to place this molecule in the proximity of the catalytic Zn(II) ion,
nor the Zn(II)-coordinated water molecule, as observed instead for other compounds (Figure 3A–D
and Figure 4A,B). The carboxylic acid group of 7 is H-bonded to the side chain of Asn-62, Lys-67,
and Thr-200, while the nitro group performed an additional H-bond with His-64. Concerning the tail
of the molecule, the sulfone group of 7 is H-bonded to Trp-5. As shown in Figure 5A, 7 is unable
to occlude the catalytic site of hCA XII, which is still accessible from the solvent area. Accordingly,
we speculate that hCA XII enzymatic reactions may still occur with compound 7 bound to the surface
of hCA XII, thus explaining the lack of inhibition by 7 observed up to high concentrations (see Table 1).
Moreover, the predicted binding mode of 7 is in agreement with the binding mode already described for
thiocoumarins [47]. As shown in Figure 5A, the carboxylic acid group of the hydrolyzed thiocoumarin
partially overlaps with that of compound 7 and does not reach the catalytic Zn(II) coordination system,
which strongly corroborates the binding mode predicted by molecular modeling.
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Figure 3. Binding mode of most promising hCA IX inhibitors predicted by molecular docking and
energy minimization. (A) Compound 1; (B) compound 7; (C) compound 10; (D) compound 15;
and (E) compound 19. Small molecules are showed as cyan sticks, the 3D structure of hCA IX is
showed as green cartoon. hCA IX residues involved in binding to compounds are showed as green
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showed as cyan sticks, the 3D structure of hCA XII is showed as yellow cartoon. hCA XII residues
involved in binding to compounds are showed as yellow lines and are labeled. H-bonds are highlighted
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3. Experimental Protocols
3.1. Selection of GV2-20 Derivatives and Molecular Modeling
Smiles representations of 6504839 commercially available compounds were downloaded from
the MolPort database (interrogated in April 2016). Molecules were subsequently filtered using
the Filter program from OpenEye (version 2.5.1.4) [56,57] by using the following SMART string
[c]1[c][c]([c][c]([c]1)[N+](=O)[O−])[C](=O)[O–] (Figure 1B, bottom panel). After filtration, a library of
1111 compounds was obtained.
Compounds selected for CAs inhibition assays were purchased from MolPort and tested
as received.
Molecular docking of most interesting compounds was performed with GOLD program
(version 5.2.1) [58]. The crystallographic structure of hCA IX isoform (PDB ID: 3IAI) at 2.2 Å
resolution [59] and hCA XII (PDB ID: 1JCZ) at 1.55 Å resolution [60] were used as rigid receptors
in the docking program. To account the three different binding hypothesis described in Section 2.3,
the binding site was centered on different positions: for hypothesis (i) and (ii), it was centered on the
catalytic Zinc(II) ion, while in the hypothesis (iii), it was centered on His-64, ND1 atom. The radius
of all binding sites was set to 14 Å. For each ligand, 30 runs of the Genetic Algorithm (GA) were
performed. The CHEMPLP scoring function was used and the GA search efficiency was increased up
to 200%. Moreover, in the binding mode hypothesis (ii) the water coordinated to the catalytic Zn(II)
ion was added in the hCA IX/hCA XII structure by aligning with the crystallographic structure of
hCA II isoform (PDB ID: 4QY3) at 1.5 Å resolution, which bears a crystallographic Zn(II)-coordinated
water molecule bound to carboxylate ion. During docking with GOLD program, the toggle state of the
Zn(II)-coordinated water molecule was set to “on”.
Ligands protonation state was assigned by fixpka application from QUACPAC (version 1.6.3.1,
OpenEye software) [61]. Finally, ligand energy minimization before docking was performed with
SZYBKI (version 1.8.0.1, OpenEye software).
The best docking-based binding pose of each compound was subsequently relaxed in explicit
water solvent with AMBER 16 [62]. The AMBER force field ff14SB [63] was used for standard amino
acids, while Zn(II) ion was modeled using the cationic dummy atom model [64]. Gaff2 force field
was used for small molecules parameters [65]. Each system was solvated by a 10 Å cuboid box of
explicit TIP3P-type water molecules. To neutralize the whole charge, the required number of Na+
counterions was then added. Water molecules were first minimized (1000 steps with the steepest
descendent algorithm (SD) and additional 2000 steps with the conjugate gradient algorithm (CG)),
while the protein was kept frozen. Then, the whole system was minimized by means of 1500 steps of
SD and 13,500 steps CG.
The electrostatic surface potential of hCA IX and hCA XII was calculated with APBS 1.4.1 with
the nonlinear Poisson−Boltzmann equation using the default parameters [66].
Figures describing ligands binding modes and electrostatic surfaces of compound 7 and hCAs
were generated with PyMol [67].
The electrostatic surface potential for compound 7 was calculated using the Schrödinger’s Maestro
Suite for molecular modelling by solving the Poisson−Boltzmann equation and using the partial
charges of the molecules 7 [68].
3.2. CA Inhibition
An applied photophysics stopped-flow instrument has been used for assaying the CA catalysed
CO2 hydration activity [54]. Phenol red (at a concentration of 0.2 mM) has been used as indicator,
working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 20 mM
Na2SO4 (for maintaining constant the ionic strength), following the initial rates of the CA-catalysed CO2
hydration reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the
determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces
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of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalysed
rates were determined in the same manner and subtracted from the total observed rates. Stock solutions
of inhibitor (0.1 mM) were prepared in distilled–deionized water, and dilutions up to 0.01 nM were
done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for
15 min at room temperature prior to assay, in order to allow for the formation of the enzyme–inhibitor
complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3
and the Cheng–Prusoff equation, as reported earlier [69–71], and represented the mean from at least
three different determinations. All CA isoforms were recombinant ones obtained in-house as reported
earlier [70–73].
4. Conclusions
Nowadays, the development of isoform-selective CAIs has become a major focus in the discovery
of innovative therapies for a wide range of human diseases.
Starting from the pan-hCAs inhibitor GV2-20, in this study we performed a tail approach in order
to improve potency and selectivity of inhibition among hCAs. Notably, almost all tested compounds
showed potent inhibition of hCA IX and increased selectivity with respect to other isoforms such as the
widely expressed cytosolic hCA I and hCA II. Of note, compound 10 emerged as the most promising
inhibitor of the tumor-associated isoforms hCA IX and hCA XII with an impressive hCA II/hCA IX
and hCA II/hCA XII selectivity index, while compound 7 was a low nanomolar and highly selective
inhibitor of hCA IX with the highest ligand efficiency. Finally, the 3-nitrobenzoic acid was confirmed
as a good scaffold for the design of CAs inhibitors.
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